Rega Institute for Medical Research

What Rega Institute for Medical Research does

The Rega Institute for Medical Research is a non-profit academic research unit embedded within KU Leuven (Katholieke Universiteit Leuven) in Leuven, Belgium, affiliated with the Department of Microbiology, Immunology and Transplantation and the Department of Pharmaceutical and Pharmacological Sciences. It conducts interdisciplinary research that combines virology, molecular and synthetic biology, and immunological profiling to study highly pathogenic viruses including yellow fever virus, SARS-CoV-2, arboviruses, norovirus, rotavirus, hepatitis E virus, and influenza. The institute is structurally organized into specialized research groups: MVVD (Molecular Vaccinology & Vaccine Discovery), VITA (Virus-Host Interactions & Therapeutic Approaches), the Porto Lab, MoViT (mosquito-borne virus research), and Trellis (AAV gene therapy vectors).

Technically, the institute's differentiating capability lies in its proprietary pre-clinical model systems, particularly human intestinal enteroids (HIEs, stem-cell-derived 3D and 2D models of the intestinal epithelium) and zebrafish larval infection models, which enable replication and study of viruses that have historically been difficult to cultivate, such as human norovirus. These platforms are combined with mosquito vector research and AAV gene therapy vector development to support antiviral drug discovery and vaccine development across multiple disease areas. The institute has produced over 183 scholarly works, including 60+ peer-reviewed articles in high-impact journals (Nature Immunology, Nature Communications, Cell & Molecular Immunology, PLOS Pathogens, Lancet Microbe, Journal of Virology, Antiviral Research).

The institute does not operate a commercial revenue model. Its funding is sourced from institutional support, government grants (primarily FWO - Research Foundation Flanders), and international foundation awards (notably the Novo Nordisk Foundation for the VirusBank Platform). Outputs are disseminated via open-access publications (LIRIAS), international conferences (ICAR, Calicivirus Conference, Zebrafish Infection and Immunity meetings), and collaborative consortia such as GUTVIBRATIONS and ISAR. Customers, in a non-commercial sense, are academic collaborators and consortium partners who benefit from shared models and infrastructure.

Name

Rega Institute for Medical Research

Legal name

Rega Institute for Medical Research

Website

https://rega.kuleuven.be

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

The Rega Institute for Medical Research is a non-profit academic research unit within KU Leuven in Belgium, conducting interdisciplinary virology research, antiviral drug discovery, and vaccine development using proprietary models such as human intestinal enteroids and zebrafish larvae.

Ownership category

akta.pro rank

Product category

Medical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Vaccine Clinical Development & Regulatory Affairs (HLAIAEAM)

Keywords

• Virology research
• Antiviral drug discovery
• Vaccine development
• Immunology research
• Translational biomedical research

Headquarters

HQ city

Leuven

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Distribution channels1 record

Marketing channels3 records

Core offering

The Rega Institute for Medical Research is a university-affiliated medical research institute within KU Leuven that conducts interdisciplinary research in virology, immunology, and vaccine development. It studies highly pathogenic viruses including yellow fever virus, SARS-CoV-2, arboviruses, norovirus, rotavirus, hepatitis E virus, and influenza, employing advanced pre-clinical model systems such as human intestinal enteroids (organoids), zebrafish larvae, and ex vivo mosquito gut cultures to support antiviral drug discovery and vaccine research. The institute houses multiple specialized research groups (VITA, MVVD, Porto Lab, MoViT, Trellis) and offers PhD training and visiting scientist programs.

Product overview

The Rega Institute for Medical Research is a research institute at KU Leuven comprising several research groups focused on virology, antiviral drug discovery, and vaccine development. The institute's research groups include: VITA (Virus-Host Interactions & Therapeutic Approaches) focused on AAV gene therapy, mosquito-borne arboviruses, and zebrafish/organoid models; MVVD (Molecular Vaccinology & Vaccine Discovery) focused on yellow fever virus, SARS-CoV-2, and next-generation vaccine design; and Porto Lab focused on norovirus, rotavirus, influenza, and hepatitis E virus using innovative model systems. The institute offers research publications database access and training opportunities for students and visiting scientists.

Differentiator

Problem solved

Functional benefit

Brands

• VITA (Virus-Host Interactions & Therapeutic Approaches): Research group focused on non-pathogenic adeno-associated virus (AAV) gene therapy, mosquito-borne arboviruses, and innovative virus infection models using zebrafish larvae and organoids.
• MVVD (Molecular Vaccinology & Vaccine Discovery)
• Porto Lab

Products and services

• VITA Research Group (Virus-Host Interactions & Therapeutic Approaches)
• MVVD (Molecular Vaccinology & Vaccine Discovery)
• Porto Lab
• Research Publications Database Access
• PhD and Visiting Scientist Training Programs

Quantifiable outcome

• Established robust HEV-HIE model yielding high titers of infectious non-enveloped virions
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• GUTVIBRATIONS ConsortiumcoreStrategic or Co-development PartnerMulti-institutional research consortium focused on gut virome and enteric virus research, with consortium update meetings held at Leuven.
• Henckaerts Lab (Trellis)coreStrategic or Co-development PartnerCollaboration on adeno-associated virus (AAV) research and gene therapy vector development, with separate lab website for Trellis research group.
• Delang Lab (MoViT)coreStrategic or Co-development PartnerMosquito-borne virus research collaboration combining molecular virology, drug discovery, and medical entomology to fight arboviral diseases.
• Porto LabcoreStrategic or Co-development PartnerResearch group focused on innovative model systems (zebrafish larvae, organoids) for virology research, studying host-pathogen interactions and viral pathogenesis.
• VITA Research GroupcoreStrategic or Co-development PartnerVirus-Host Interactions & Therapeutic Approaches unit combining Trellis, MoViT, and Porto Lab research groups under Prof. Els Henckaerts leadership.
• MVVD (Molecular Vaccinology & Vaccine Discovery)coreStrategic or Co-development PartnerVirology, Antiviral & Vaccine Research group at KU Leuven combining virology, molecular biology, and immunological profiling for next-generation vaccine design against pathogens including yellow fever virus and SARS-CoV-2.
• Molvax.beminorStrategic or Co-development PartnerExternal platform for information about the Molecular Vaccinology & Vaccine Discovery team, research, and opportunities.
• International Society for Antiviral Research (ISAR)coreStrategic or Co-development PartnerInternational professional society organizing the International Conference on Antiviral Research (ICAR). Researchers actively participate in and present at annual ICAR conferences, contributing to global antiviral research community.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Helmholtz Centre for Infection Research: Large German government research center focused on infection biology, antiviral drug discovery, and vaccine development. Comparable in mission and translational pipeline scope to Rega's MVVD and VITA groups.
• Max Planck Institute for Infection Biology: German academic research institute conducting fundamental and translational research on infectious diseases and immunology. Comparable to Rega as a discovery-driven virology center with strong publication record and graduate training programs.
• The Francis Crick Institute: Large UK biomedical research institute conducting foundational and translational research across infection and immunity, including virology and vaccine biology. Comparable to Rega as a multidisciplinary academic virology research center.
• Pasteur Institute: Major French non-profit biomedical research institute with deep expertise in virology, vaccine development, and infectious diseases. Directly comparable to the Rega Institute as a national-level academic virology center with international consortia participation and antiviral discovery programs.

Direct peers

• Texas Biomedical Research Institute: US-based independent biomedical research institute with significant programs in virology, BSL-level infectious disease research, and antiviral/vaccine development. Comparable to Rega as a non-university-affiliated independent research entity focused on viral pathogenesis.
• Institut Pasteur de Lille: French research institute focused on infectious disease, virology, and vaccine research within the Pasteur network. Directly comparable to Rega as a virology-focused research center with active vaccine and antiviral discovery programs.
• Bernhard Nocht Institute for Tropical Medicine: German research institute specializing in tropical virology, arboviruses, and emerging infectious disease research. Directly comparable to Rega's MoViT arbovirus and emerging-pathogen programs, with similar academic funding model and WHO-reference laboratory functions.

Emerging players

• La Jolla Institute for Immunology: Independent US research institute focused on immunology and infectious disease, with deep immunological profiling capabilities. Comparable to Rega's MVVD group's integration of immunology and virology for vaccine design.
• Rockefeller University - Laboratory of Virology and Infectious Disease: US-based academic research university with active virology and infectious disease laboratories focused on hepatitis, enteric viruses, and emerging pathogens. Comparable to Rega's hepatology/enteric virus work and mechanistic virology emphasis.

Regional players

• Institute of Tropical Medicine Antwerp: Belgian academic research institute focused on tropical and infectious diseases, including antiviral and vaccine research. Closest geographic peer to Rega, with overlapping tropical pathogen focus (arboviruses, hepatitis, enteric viruses) and translational virology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/kuleuven
• YouTubeyoutube.com/user/kuleuven
• Facebookfacebook.com/KULeuven
• LinkedInlinkedin.com/company/rega-institute-for-medical-research
• Instagraminstagram.com/kuleuven

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rega Institute for Medical Research